Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

A MULTIDIMENSIONAL BENEFIT???

February 23, NeuroRx said the Phase IIb/III COVID-AIV trial (NCT04311697) of Zyesami (aviptadil, previously RLF-100™) for the treatment of respiratory failure in critically ill patients with COVID-19 has shown multidimensional benefit around its prespecified primary endpoint of recovery from respiratory failure with discharge from hospital and ICU (without relapse) by day 28 in patients with critical COVID-19 who were treated with High Flow Nasal Oxygen. The trial was conducted at 10 U.S. hospitals under the direction of NeuroRx and its Swiss partner Relief Therapeutics.
https://www.genengnews.com/covid-19-candidates/relief-therapeutics/

The size of the COVID-19 vaccine market across the seven major markets – the US, Germany, France, Italy, Spain, the UK, and Japan -will increase from $13.6bn in 2021 to $19.5bn in 2026 at a compound annual growth rate (CAGR) of 7.6% should annual vaccination be required, according to GlobalData.

https://www.pharmaceutical-technology.com/news/covid-19-vaccine-market-set-to-reach-19-5bn-by-2026-register-for-free-webinar/

WILL INFLUENZA BE NEXT???

ARDS is predominantly an inflammatory process that can be caused by a primary or secondary trigger. Influenza acts as a primary etiology and when there is an exaggerated inflammatory response the result can be severe respiratory failure.

https://www.aarc.org/nn19-ecls-in-influenza-related-ards/

Influenza Vaccine Market to Hit USD 7.60 Billion with 6.9% CAGR by 2027; Increasing Geriatric Population to Stoke Demand: Fortune Business Insights™

https://www.globenewswire.com/en/news-release/2021/03/10/2190110/0/en/Influenza-Vaccine-Market-to-Hit-USD-7-60-Billion-with-6-9-CAGR-by-2027-Increasing-Geriatric-Population-to-Stoke-Demand-Fortune-Business-Insights.html